Sarclisa (Isatuximab-irfc) for Myeloma

Overview
Sarclisa is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor. Sarclisa is also known by its drug name, isatuximab-irfc.

Sarclisa is used as a targeted therapy for multiple myeloma. Sarclisa is a member of a class of drugs called monoclonal antibodies. Sarclisa is believed to work by binding to the surface of abnormal cells, causing cell death.

How do I take it?
Prescribing information states that Sarclisa is given as an intravenous infusion (slow injection into your vein) by a health care professional. Sarclisa is usually given in a health clinic or doctor’s office. It should be administered according to the frequency specified by the physician.

Sarclisa is available only as an intravenous infusion.

Side effects
The FDA-approved label for Sarclisa lists common side effects that include anemia (low red blood cell count), neutropenia (low white blood cell count), thrombocytopenia (low blood platelet count), pneumonia, and diarrhea.

Serious side effects listed for Sarclisa include infusion-related reactions and fetal harm.

For more details about this treatment, visit:

Sarclisa — Sanofi
https://www.sarclisa.com/

Isatuximab-irfc — Chemocare
http://chemocare.com/chemotherapy/drug-info/isatuximab.aspx